In order to better guide clinical safe and rational drug use, our company, in accordance with the requirements of the announcement (No. 20 of 2023) issued by the National Medical Products Administration regarding the "Special Provisions for Drug Registration Management of Traditional Chinese Medicine", has actively carried out a listing study on the safety information items of Daqi Li San. We have revised the contents of the instructions and labels regarding "Adverse Reactions", "Contraindicatio
View details ❯